Related Experiment Video
Updated: Aug 21, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Silencing RIPK1/mTORC1 signalling attenuated the inflammation and oxidative stress in diabetic cardiomyopathy
Qin Liu1, Changqing Deng2, Xianliang Xing1
1Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, PR China.
Background:
Diabetes cardiomyopathy (DCM) is one of the major risk factors for the heart failure of the diabetic patients. RIPK1 maybe participate in the regulation of the oxidative stress and inflammation during DCM.
Methods:
H&E and Masson staining were utilized to assess the inflammation and fibrosis in myocardial tissues. CCK-8 and TUNEL staining were utilized to analyze cell viability and apoptosis, respectively. SOD activity and MDA content were detected utilizing the kits. The formation of autophagosomes was measured by immunofluorescence assay.
Results:
RIPK1 and RPTOR (a component of mTORC1) expression and oxidative stress level were upregulated, but autophagy was decreased in the myocardial tissues of DCM rat characterized by the high body weight and blood glucose, abnormal cardiac function, myocardial inflammation and fibrosis. High glucose (HG) treatment resulted in cell viability and autophagy level decreasing, inflammatory cytokines expression increasing and oxidative stress increasing in cardiac fibroblasts (CFs). Meanwhile, RIPK1 and RPTOR expression also was increased in HG-treated cells. HG-induced CFs apoptosis, inflammation, oxidative stress and the inhibition of HG to cell viability and autophagy was partly reversed by the inhibitor of RIPK1 and mTORC1.
Conclusion:
Overall, RIPK1/mTORC1 signalling suppression improved HG-induced apoptosis, inflammation and oxidative stress through activation autophagy. These data provided a reliable evidence that RIPK1 may be a potential target for DCM therapeutic.
Insights
Receptor-interacting protein kinase 1 (RIPK1) and mTORC1 signaling suppression improved high glucose-induced diabetes cardiomyopathy (DCM) by activating autophagy. This suggests RIPK1 as a potential therapeutic target for DCM.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Diabetology
Background:
- Diabetes cardiomyopathy (DCM) is a significant risk factor for heart failure in diabetic patients.
- Receptor-interacting protein kinase 1 (RIPK1) may play a role in regulating oxidative stress and inflammation in DCM.
Purpose of the Study:
- To investigate the role of RIPK1 and mTORC1 signaling in high glucose-induced diabetes cardiomyopathy (DCM).
- To explore the potential of targeting RIPK1/mTORC1 signaling for DCM therapeutic strategies.
Main Methods:
- Assessed myocardial inflammation and fibrosis using H&E and Masson staining in DCM rats.
- Analyzed cell viability and apoptosis with CCK-8 and TUNEL assays.
- Measured oxidative stress markers (SOD, MDA) and autophagosome formation via immunofluorescence.
Main Results:
- DCM rat hearts showed upregulated RIPK1, RPTOR, and oxidative stress, with decreased autophagy.
- High glucose (HG) treatment in cardiac fibroblasts (CFs) reduced viability and autophagy, increased inflammation, oxidative stress, and RIPK1/RPTOR expression.
- Inhibiting RIPK1 and mTORC1 partially reversed HG-induced apoptosis, inflammation, and oxidative stress, while enhancing cell viability and autophagy.
Conclusions:
- Suppression of RIPK1/mTORC1 signaling ameliorates high glucose-induced apoptosis, inflammation, and oxidative stress by activating autophagy.
- RIPK1 inhibition represents a promising therapeutic target for managing diabetes cardiomyopathy.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Coronary Artery Disease I: Introduction
Myocarditis I: Introduction
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Cardiomyopathy IV: Restrictive Cardiomyopathy

